What are the symptoms of bipolar II depression, and is aripiprazole (Abilify) an appropriate treatment considering the risk of apathy?

Bipolar II Depression: Symptoms and Aripiprazole Treatment

Aripiprazole (Abilify) is NOT a first-line treatment for bipolar II depression based on current evidence, and while it may paradoxically help apathy in some cases, standard doses carry significant risk of causing apathy and sedation as adverse effects.

Symptoms of Bipolar II Depression

Bipolar II disorder presents primarily with depressive episodes that are clinically indistinguishable from unipolar depression, but patients also experience hypomanic episodes (not full mania). The depressive symptoms include:

• Persistent low mood and anhedonia
• Significant psychosocial dysfunction
• High risk of misdiagnosis as unipolar depression since patients typically present during depressive phases rather than hypomanic phases 1
• The misdiagnosis risk is critical because inappropriate antidepressant monotherapy can induce manic switching or rapid cycling 1

Aripiprazole for Bipolar II Depression: The Evidence

Efficacy Concerns

Aripiprazole has failed to demonstrate efficacy for acute bipolar depression in controlled trials 2. Two randomized studies showed that while aripiprazole reduced depressive symptoms early in treatment, results were not significantly different from placebo at the primary endpoint of 8 weeks 2. The negative findings have been attributed to:

• High study doses (typically 10-30 mg)
• Rapid titration schedules
• High placebo response rates 2

The Low-Dose Exception

However, there is compelling evidence that LOW doses (1-5 mg) may be effective specifically for bipolar II depression 3. A 2017 study of 211 patients with bipolar II or bipolar NOS depression found that doses of 5 mg or less were associated with significant improvement, with patients rated as "improved or very much improved" compared to baseline. Only 16 of 211 patients experienced no change or worsening 3. The key is starting with very low doses and allowing time to respond 3.

Guideline Recommendations

The 2018 CANMAT/ISBD guidelines do NOT list aripiprazole as a first-line treatment for bipolar depression 4, 5. First-line options for bipolar I depression include:

• Quetiapine
• Lurasidone (alone or with lithium/divalproex)
• Lithium
• Lamotrigine 4

For bipolar II specifically, the evidence base is even more limited, and aripiprazole is not prominently featured in treatment algorithms 4.

The Apathy Question: A Critical Paradox

Aripiprazole CAUSES Apathy as an Adverse Effect

According to FDA labeling, common adverse effects of aripiprazole include 6:

• Sedation (21% in pediatric trials)
• Fatigue (8-17% depending on population)
• Lethargy (5%)
• Somnolence (10-23%)

These symptoms overlap significantly with apathy presentation. In pediatric bipolar mania trials, fatigue occurred in 11% on aripiprazole vs 4% on placebo 6.

But It May TREAT Apathy in Select Cases

Paradoxically, one case report suggests aripiprazole (15 mg) improved apathy syndrome in a patient with depression, theoretically through its partial dopamine D2 agonist activity 7. The authors note that SSRIs can cause or worsen apathy, and dopamine agonists may help 7.

This creates a clinical dilemma: Standard doses cause apathy-like symptoms in many patients, but the medication's dopaminergic activity might help true apathy in others.

Clinical Algorithm for Decision-Making

When to Consider Aripiprazole for Bipolar II Depression:

1. Only after first-line treatments have failed (quetiapine, lamotrigine, lithium, lurasidone)
2. Start with 1-2 mg daily (not the standard 10-15 mg) 3
3. Titrate slowly - increase by 1-2 mg every 2-4 weeks only if needed
4. Maximum dose should rarely exceed 5 mg for bipolar II depression 3
5. Allow 6-8 weeks to assess response before abandoning treatment

Monitoring for Apathy/Sedation:

• Weekly assessment for first month looking specifically for:
  • Increased sedation or fatigue
  • Reduced motivation or initiative
  • Worsening functional capacity
  • Akathisia (which can mimic or worsen restlessness) 6

When NOT to Use Aripiprazole:

• As first-line treatment for bipolar II depression
• If patient already has significant apathy or amotivation
• If patient has had prior negative response to dopamine-blocking agents
• During acute hypomania or mixed features 8

Critical Caveats

The FDA black box warning applies: Monitor for suicidality, especially in younger patients, particularly during initial treatment and dose changes 6. Families should be educated to watch for agitation, irritability, unusual behavior changes, and emerging suicidality 6.

For bipolar II patients specifically, mood stabilizer coverage may be at clinician's discretion (unlike bipolar I where it's mandatory) 8, but given the risk of mood destabilization, concurrent mood stabilizer use is prudent.

The evidence for aripiprazole preventing depressive relapse is weak - maintenance studies show it prevents manic but not depressive relapses 2, 9.

Bottom Line

Use quetiapine, lamotrigine, lithium, or lurasidone as first-line treatments for bipolar II depression 4. If considering aripiprazole after first-line failures, use only low doses (1-5 mg), start very low, and monitor closely for both therapeutic response and emergence of apathy/sedation. The standard doses used in clinical trials (10-30 mg) are likely too high and poorly tolerated for bipolar depression 3, 2.